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Amiodarone hydrochloride is one of the most important drugs used to treat arrhythmias. The USP 
monograph for amiodarone hydrochloride describes an HPLC method for the quantification of seven 
impurities, however, this method shows problems that result in unresolved peaks. Moreover, there is no 
monograph for tablets in this compendium. Thus, a stability indicating HPLC method was developed for 
the determination of amiodarone, its known impurities and degradation products in tablets. A detailed 
forced degradation study was performed submitting amiodarone API, tablets and placebo to different stress 
conditions: acid and alkaline hydrolysis, oxidation, metal ions, heat, humidity, and light. Amiodarone 
hydrochloride API was susceptible to degradation in all stress conditions. The tablets also showed 
degradation in all environments, except in acidic condition. The analytes separation and quantification 
were achieved on an Agilent Zorbax Eclipse XDB-C18 column (100 x 3.0 mm, 3.5 µm). The mobile 
phase was composed of 50 mM acetate buffer pH 5.5 (A) and a mixture of methanol-acetonitrile (3:4, 
v/v) (B) in gradient elution. The method was validated in the range of 350-650 µg/mL for assay and 
10-24 µg/mL for impurities determination. Therefore, this method can be used both for stability studies 
and routine quality control analyses.
Keywords: Amiodarone hydrochloride. Impurities. Forced degradation. Stability indicating methods. 
High-performance liquid chromatography.
INTRODUCTION
Cardiovascular diseases are the number one cause of 
death in the world. It is estimated that 17.7 million people 
died in 2015 from cardiac diseases, representing 31% of 
all global deaths (WHO, 2018). Among cardiovascular 
diseases, arrhythmia can be defined as an abnormal heart 
rhythm. This means that the electrical impulses of the 
heart can happen faster, slower or erratically. Arrhythmias 
can range from asymptomatic and transitory clinical 
findings to life-threatening abnormalities (American Heart 
Association, 2018).
Amiodarone hydrochloride (Figure 1) is one of 
the drugs used to treat arrhythmias, although none of its 
pharmacological effects is clearly related to arrhythmia-
suppressing properties (Mason, 1993). Oral amiodarone 
is indicated to treat patients with recurrent ventricular 
tachycardia, fibrillation resistant to other drugs and to 
maintain sinus rhythm in patients with atrial fibrillation 
(Connolly, 1999). Despite its potential for serious adverse 
effects and uncertainties about its mechanism of action, 
amiodarone is one of the first-line drugs for the treatment 
of common cardiovascular diseases (Roden, 2010).
Amiodarone hydrochloride is used worldwide 
and its monograph is described in a large number of 
pharmacopeias, including the United States Pharmacopoeia 
(USP, 2017) and the British Pharmacopoeia (BP, 2018). 
The monographs for amiodarone hydrochloride raw 
material presented in those pharmacopeias describe 
an isocratic reversed-phase HPLC method for the 
quantification of seven impurities (A-G) (Figure 1). The 
same analytical conditions are presented for amiodarone 
tablets monographs in BP and USP Pharmacopeial Forum. 
Additionally, these compendia report other methods for 
the quantitative amiodarone assay (BP, 2018; USP, 2018).
Karmakar et al. (2014) observed problems with 
the USP method for amiodarone related substances that 
resulted in unresolved peaks due to impurities A, D and 
E. The authors optimized the USP method using quality 
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by design approach and altered the column brand, column 
temperature and pH of the mobile phase. However, they 
did not perform a forced degradation study to verify the 
separation of the related compounds in the presence of 
degradation products.
It is known that forced degradation tests are the 
main tool to predict drug degradation, to identify possible 
degradation products of an active pharmaceutical ingredient 
(API) or drug product and to develop stability indicating 
methods. Therefore, it is not possible to guarantee that a 
method is stability indicating only because it is capable 
of separating some known impurities (Baertschi, Alsante, 
Reed, 2011; Bakshi, Singh, 2002; Silva et al., 2009).
Khan et al. (2005) developed an isocratic HPLC 
method for the estimation of purity and quantitative 
determination of amiodarone API in the presence of five of 
its known impurities. In order to demonstrate the specificity 
of the method, samples of amiodarone were subjected 
to various stress conditions such as acid, base, hydrogen 
peroxide, heat, humidity, and light. Amiodarone presented 
significant degradation (8%) only under acidic hydrolysis.
Christopherson, Yoder, and Miller (2004) developed a 
gradient HPLC method for the determination of amiodarone 
and two of its known impurities in amiodarone injection. 
The authors described a degradation study submitting 
amiodarone to acid, base, peroxide, heat and light 
conditions. Amiodarone was stable under all conditions, 
except for photolytic treatment (13% degradation).
Despite being an important and widely used drug, 
there are only a few studies reporting the stability of 
FIGURE 1 - Chemical structures of amiodarone hydrochloride and its impurities (A-G).
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amiodarone under stress conditions. Furthermore, the 
stability indicating methods described do not prove to 
be able to resolve the peaks due to the seven known 
amiodarone impurities and the degradation products.
In this context, the aim of this study was to perform 
a detailed and comprehensive study to evaluate the 
stability of amiodarone in API and tablets under acidic, 
alkaline, oxidative, heat, humidity and light conditions 
and in the presence of metal ions, according to current 
legislation (Anvisa, 2015). Furthermore, a simple and 
selective gradient HPLC stability indicating method 
for quantification of amiodarone and its seven related 
compounds in the presence of its degradation products 
was developed and validated.
MATERIAL AND METHODS
Reagents and standards
Amiodarone hydrochloride reference standard was 
obtained from Fiocruz (Rio de Janeiro, Brazil). Impurities 
D and E were purchased from U.S. Pharmacopeial 
Convention (Rockville, USA) and impurities A, B, C, F, and 
G were obtained from PGS (San Francisco, EUA). Tablets 
containing 200 mg of amiodarone hydrochloride and 
placebo were provided by Hipolabor Farmacêutica (Sabará, 
Brazil). Amiodarone hydrochloride API was purchased 
from Zhejiang Sanmen (Sanmen, China). The reagents 
used for the analysis were: acetonitrile (ACN), methanol 
(MeOH) and dimethyl sulfoxide (DMSO) from Merck 
(Darmstadt, Germany), hydrogen peroxide from Soltech 
(Rio de Janeiro, Brazil) and acetic acid, hydrochloric 
acid, iron (III) sulfate, ammonium hydroxide and sodium 
hydroxide from Neon (São Paulo, Brazil). Purified water 
was obtained from an Elga Purelab Option-Q system.
Preparation of mobile phase and diluent
The diluent was prepared by mixing 500 mL of 
ACN and 500 mL of purified water. Mobile phase A was 
prepared by mixing 3 mL of acetic acid and 1000 mL of 
purified water. In the optimized phase, pH was adjusted 
to 5.5 with ammonium hydroxide. Mobile phase B was 
composed of 300 mL of MeOH and 400 mL of ACN. After 
preparation, both mobile phases were filtered through a 
0.22 µm filter.
Instrumentation and analytical conditions
Chromatography was carried out using a Thermo 
Ultimate 3000 HPLC system equipped with a quaternary 
gradient pump, an autosampler, a column oven, and a 
photodiode array detector. Software Chromeleon 7 was 
used for data acquisition and analysis. Separation was 
performed on an Agilent Zorbax Eclipse XDB-C18 
column (100 x 3.0 mm, 3.5 µm). After optimization, 
the column was maintained at 50 °C. A gradient elution 
was used (Table I), with a flow rate of 0.7 mL/min. 
The injection volume was 2 µL and UV detection was 
performed at 240 nm.
Preparation of impurities mix standard for 
method development
Separate standard stock solutions of amiodarone 
hydrochloride and of each impurity (A-G) at a concentration 
of 500 µg/mL were prepared by dissolving an accurately 
weighed amount of 5 mg in 10 mL of methanol. Then, 
aliquots of 1 mL of each stock solution were taken and 
transferred to a 10 mL volumetric flask. The volume was 
completed with diluent. The final concentration of each 
analyte was 50 µg/mL. 
Preparation of standard and sample solutions for 
the assay testing
The assay test was performed at 500 µg/mL of 
amiodarone hydrochloride. The standard stock solution 
was prepared by weighing 50 mg of amiodarone 
hydrochloride reference standard and transferring to 
a 50 mL volumetric flask. The volume was completed 
with methanol. Then, an aliquot of 5 mL of this solution 
was taken and transferred to a 10 mL volumetric flask. 
The volume was completed with diluent. For the sample 
preparation, 20 tablets were accurately weighed and 
ground to fine powder. An amount of powder equivalent 
to 50 mg of amiodarone hydrochloride was dissolved in 
50 mL of methanol. An aliquot of 5 mL of this solution 
was taken and transferred to a 10 mL volumetric flask. The 
volume was completed with diluent.
TABLE I - Mobile phase gradient used








Mobile phase A: 50 mM acetate buffer pH 5.5; Mobile phase B: 
mixture of methanol-acetonitrile (3:4, v/v).
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Preparation of standard and sample solutions for 
impurities determination
The sample solution was prepared at a concentration 
of 10 mg/mL for amiodarone hydrochloride, dissolving an 
amount of powder equivalent to 100 mg of amiodarone 
hydrochloride in 10 mL of methanol. The standard 
solution was prepared at a concentration of 20 µg/mL of 
amiodarone hydrochloride, corresponding to the specified 
limit for impurities (0.2%). An aliquot of 4 mL of the assay 
standard solution (500 µg/mL) was taken and transferred 
to a 100 mL volumetric flask. The volume was completed 
with diluent. All impurities were calculated in comparison 
to the amiodarone peak.
Forced degradation
A comprehensive forced degradation study was 
performed submitting amiodarone hydrochloride API, 
tablets and placebo to different stress conditions: acidic, 
alkaline, oxidative, metal ions, heat, humidity, and light. 
In dry heat condition, the API, placebo and tablets powder 
were submitted to high temperature (105 ºC in an oven) 
for seven days. The influence of humidity on stability was 
tested by exposing the samples powders in a 420/CLD 
stability cabinet (Nova Ética) to 40 ºC and 75 ± 5% relative 
humidity for five days. Light stress studies were performed 
subjecting the samples powder to the UV-A radiation 
(200 Wh/m2) and visible radiation (1.2 million lux-hours) 
during five days. To prepare the samples submitted 
to hydrolytic degradation, oxidation (with hydrogen 
peroxide) and degradation by metal ions, approximately 
50 mg of amiodarone hydrochloride were accurately 
weighed and transferred to 50 mL volumetric flasks, 
followed by the addition of 5 mL of cosolvent (DMSO 
was used for alkaline hydrolysis and MeOH for the other 
conditions). Then, 10 mL of degradation solutions were 
added, and the samples were exposed to the following 
conditions: acid hydrolysis (5.0 M HCl solution at 25 ºC 
for 5 days), alkaline hydrolysis (1.0 M NaOH solution 
at 60 ºC for 15 hours), oxidation (30% H2O2 solution at 
25 ºC for 3 days) and metal ions (0.1 M Fe2(SO4)3 solution 
at 25 ºC for 2 days). After this period, resulting solutions 
were neutralized, if applicable, and diluted to 50 mL 
with methanol. Then, aliquots of 5 mL of each solution 
were taken and transferred to 10 mL volumetric flasks. 
The volume was completed with diluent. These solutions 
were filtered and injected in the chromatographic system. 
Solutions of placebo and diluent employed for preparing 
the samples in each stress condition were injected in order 
to evaluate the presence of possible interference peaks. 
The control samples were also prepared without adding 
the degradation solutions to quantify the percentages of 
amiodarone degradation.
Method validation
The stability-indicating method was validated 
for  assay and related substances fol lowing the 
recommendations described in the Brazilian legislation 
RDC Nº 166/2017 (Anvisa, 2017) and in ICH Guidance for 
Industry Q2 (R1) Validation of Analytical Procedures: Text 
and Methodology (ICH, 2005). Some acceptance criteria 
applied were defined based on the Guidelines for Standard 
Method Performance Requirements (AOAC, 2016). The 
following parameters were evaluated: selectivity, limit 
of detection (LOD) and limit of quantification (LOQ), 
linearity, precision, accuracy, robustness, and stability of 
solutions.
Selectivity
Selectivity of the developed method was proved 
by stress degradation studies in which the drug was 
intentionally degraded under different stress conditions 
(Anvisa, 2015). The presence of interferents in the 
retention time of amiodarone and its known impurities was 
evaluated. The acceptance criteria for adequate separation 
was the resolution value greater than 1.5. Moreover, 
the peak purity was analyzed using a photodiode array 
detector.
LOD and LOQ
Limits of detection and quantitation were estimated 
at a signal to noise ratio of 3:1 and 10:1 respectively, 
according to ICH (2005). For this approach, decreasing 
analyte concentrations were analyzed.
Linearity
Linearity was evaluated in two ranges, one for 
impurities and the other for assay. For impurities 
determination, linearity was evaluated at six concentration 
levels, corresponding from 0.10% to 0.24% of the working 
concentration (10 mg/mL). The linearity of the assay 
was determined in the range from 70% to 130% of the 
working concentration (500 µg/mL) using five different 
concentration levels. In both cases, solutions were 
prepared in triplicate. The obtained data were statistically 
analyzed to prove that they met the assumptions for a 
linear regression. The Grubbs test was used in order 
to evaluate the presence of outliers. Shapiro-Wilk and 
Cochran tests were performed to assess the normality and 
homoscedasticity of residuals, respectively (Cochran, 
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1941; Shapiro, Wilk, 1965; Souza, Junqueira, 2005). Also, 
the regression significance and adjustment to the linear 
model were evaluated.
Precision
For the impurities method, the intra-day precision 
was evaluated by carrying out six preparations of placebo 
spiked with amiodarone hydrochloride at 0.20% of 
nominal sample concentration. The inter-day precision 
was performed by repeating the same procedure on 
another day by another analyst. The precision of the assay 
method was assessed in terms of intra-day and inter-day 
precision by the quantification of amiodarone in six 
independent replicates prepared at 100% of the working 
concentration. Results were reported in terms of relative 
standard deviation (RSD).
Accuracy
To assess accuracy, placebo was spiked with known 
amounts of amiodarone hydrochloride in three levels: 
0.10%, 0.20% and 0.24% of the working concentration 
for impurities (10 mg/mL) and 70%, 100% and 130% 
of the working concentration for the assay (500 µg/mL). 
Each solution was prepared in triplicate and the recovery 
percentage of amiodarone was calculated.
Robustness
The robustness of the method was evaluated 
analyzing samples prepared in the precision test. Samples 
were assayed under nominal conditions and by the 
variation of the following analytical parameters: column 
temperature (48 and 52 ºC), flow rate (0.6 and 0.8 mL/min), 
buffer pH (5.3 and 5.7) and column batch. Moreover, the 
retention factor, tailing factor, and theoretical plate number 
were evaluated for five injections of the standard solution 
in each condition to set the system suitability parameters.
Stability of solutions
The standards and samples solutions used in the 
precision test were stored in the autosampler in amber 
glass vials at 10 ºC. Solutions were analyzed by the HPLC 




In order to optimize the stability indicating method, 
the impurity mixture standard was employed. Different 
columns were used and the best results were obtained 
with Agilent Zorbax Eclipse XDB-C18 (100 x 3.0 mm, 
3.5 µm). The column temperature was tested in the range 
of 25 °C to 50 °C. The peak shape was improved increasing 
temperature. Thus, the temperature was set at 50 °C. It is 
known that changes in the pH of the mobile phase are one 
of the best strategies to enhance the resolution between 
acidic or basic substances. Amiodarone hydrochloride is a 
weak base with a pKa value of 6.56. The pka values for the 
impurities were predicted using MarvinSketch software 
(ChemAxon, Budapest, Hungary) and the following values 
were obtained: 8.58 (impurity A), 9.40 (impurity B), 8.52 
(impurity C), 5.61 (impurity D), 7.80 (impurity E), 6.70 
(impurity F) and 8.47 (impurity G). Amiodarone and its 
impurities have similar chemical structures and properties. 
Because of that, it is hard to predict the behavior of these 
analytes, especially considering pKa only. Thus, during the 
method development, the pH of the buffer was tested in 
the range of 3.0 to 6.0. The resolution between the critical 
peak pair (impurities E and A) was higher with pH 5.5, 
therefore, this condition was set. Several gradients were 
tested and the one with the best results is shown in Table I. 
The chosen wavelength was 240 nm, once amiodarone and 
its impurities showed a good absorption at this condition. 
The chromatogram obtained for the standard mixture, in 
the optimized condition, is shown in Figure 2.
Forced degradation
Table II shows a summary of the results obtained 
in the forced degradation study for both API and tablets. 
In acidic hydrolysis, 5.0 M HCl was used for 120 hours. 
Amiodarone API showed around 10% degradation, while 
amiodarone tablets were stable. The only degradation 
product formed with amiodarone API was impurity B. 
In alkaline hydrolysis, amiodarone API and tablets were 
exposed to 1.0 M NaOH for 15 hours at 60 °C in an oven. 
Both API and tablets showed degradation over 20%. 
The chromatogram obtained for amiodarone tablets is 
shown in Figure 3. Impurity D was formed, with several 
unknown impurities. Two kinds of oxidations mechanisms 
were tested. With 30% H2O2 for 96 hours, both API and 
tablets showed degradation over 20%. The chromatogram 
obtained for tablets is shown in Figure 4. There was 
a formation of one unknown impurity, with a relative 
retention time (RRT) of 0.47, and impurities B, C and 
D. With 0.1 M Fe2(SO4)3 for 48 hours, only amiodarone 
API showed degradation over 10%. Impurities B and 
D were formed in this condition. When exposed to dry 
heat (105 °C for 168 hours), amiodarone tablets and API 
showed degradation around 10%. Impurities B, C, D, E, 
and F were formed for amiodarone tablets, as well as an 
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unknown impurity with RRT of 0.47. The chromatogram 
obtained is shown in Figure 5. After exposure to humid 
heat (40 °C and 75% R.H. for 120 hours), only amiodarone 
API showed degradation over 10%. Two unknown 
impurities were formed, with RRT of 0.47 and 0.59. Also, 
impurities B and D were formed, for both API and tablets. 
Amiodarone API was more susceptible to photolysis than 
tablets when exposed to UV light for 120 hours. After the 
exposure, there was a formation of impurities B, C and D 
and an unknown impurity with RRT of 0.47. The extent 
of degradation under all conditions tested was lower 
for tablets than for API. The main degradation products 
formed in all conditions were impurities B, C and D and 
an unknown impurity with RRT of 0.47. The optimized 
method was able to resolve the peaks due to amiodarone, 
its known impurities, and degradation products.
A literature survey revealed that only two forced 
degradation studies for amiodarone hydrochloride are to 
be found (Christopherson, Yoder, Miller, 2004; Khan et al., 
2005). However, both used mild stress conditions that 
resulted in a small extent of amiodarone degradation. 
In this study, the stress conditions employed resulted 
FIGURE 2 - Representative chromatogram of the impurity mixture standard.
TABLE II - Results obtained in the forced degradation study for 







5.0 M HCl – 120 h 9.51 1.97
1.0 M NaOH – 60 °C – 15 h 30.82 20.35
30% H2O2 – 96 h 34.93 21.61
0.1 M Fe2(SO4)3 – 48 h 30.82 7.89
105 °C – 168 h 11.99 8.38
40 °C, 75% R.H. – 120 h 15.04 6.92
UV light – 120 h 16.44 7.11
FIGURE 3 - Representative chromatogram of amiodarone hydrochloride tablets after degradation by alkaline hydrolysis.
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in amiodarone degradation under all conditions and in 
adequate extension (about 10 to 30%). It is hard to compare 
the degradations obtained, once the pharmaceutical forms 
used are different and API from different manufacturers 
can lead to distinct degradation profiles.
Method validation
Selectivity
The selectivity of the method was investigated by 
injecting the stress samples. There were no peaks eluting 
in the same retention time than amiodarone, its related 
substances or degradation products peaks. All peaks were 
well separated and the resolution was in all cases not less 
than 1.5. Moreover, a photodiode array detector was used 
to scan the amiodarone and all known impurities peaks in 
the range from 200 to 400 nm. Spectra indicated that no 
co-elution was present, once the purity match was above 
950, according to Chromeleon 7 software.
LOD and LOQ
Employing the signal-to-noise ratio method, the 
detection and quantitation limits were 8 µg/mL and 9 µg/
mL, respectively.
Linearity
Statistical tests were used to verify if the obtained 
data met the premises for the use of the ordinary least 
squares method. The results obtained for the tests of 
normality and homoscedasticity of residuals showed that 
the residuals are in agreement with all the least squares 
method assumptions. Moreover, the residuals presented 
random distribution, the regression was statistically 
significant and lack of adjustment to the linear model 
was not observed. The equations of the calibration curves 
obtained were y = 147.54 x + 44.734 for impurities method 
and y = 151.12 x − 877.23 for assay method. For both of 
them, the correlation coefficient was higher than 0.990, 
as required by the validation guideline (Anvisa, 2017). 
FIGURE 4 - Representative chromatogram of amiodarone hydrochloride tablets after degradation by oxidation.
FIGURE 5 - Representative chromatogram of amiodarone hydrochloride tablets after degradation by dry heat exposure.
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Precision
For the impurities method, the RSD obtained 
was 5.2%, for both intra-day and inter-day precision. 
Concerning the assay method, the RSD obtained in the 
intra-day and inter-day precision were 1.0% and 1.2%, 
respectively (Table III). The developed method was found 
to be precise as the RSD values were less than 5.3% for 
impurities and 2.0% for the assay (AOAC, 2016).
Accuracy
Accuracy was assessed using placebo solutions 
spiked with known amounts of amiodarone hydrochloride 
in three levels. The recovery percentages were between 
90.0 and 107.0% for impurities and 98.0 and 102.0% for 
assay. Moreover, the RSD values were below 5.3% and 
2.0%, respectively (Table IV) (AOAC, 2016).
Robustness
In the robustness study, each chromatographic factor 
selected was changed one by one to estimate the effect of 
the change on the results. The method was not robust only 
for changes in the pH of the buffer solution, and therefore, 
this parameter must be properly controlled.
Stability of solutions
Solutions were considered stable for 72 hours since 
no evidence of degradation of the analyte was observed 
until this time.
CONCLUSIONS
A comprehensive stability study was carried 
out, subjecting samples of amiodarone hydrochloride 
API and tablets to degradation by acid and alkaline 
hydrolysis, oxidation, metal ions, heat, humidity, and 
light. Amiodarone hydrochloride API was susceptible 
to degradation in all stress conditions. The tablets also 
showed degradation in all environments, except in acidic 
condition. Moreover, in all cases, the extent of degradation 
for the tablets was lower than for the API. In this sense, the 
use of proper adjuvants and packaging materials should 
be considered during drug product development. The 
developed stability-indicating method was completely 
validated showing to be selective, linear, precise, accurate 
and robust and can be used both for stability studies and 
routine quality control analyses.
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